RESUMO
Immunoglobulin class plays an important role in the histocompatibility crossmatch test to predict hyperacute rejection in kidney transplantation. The existing data indicates that immunoglobulin (Ig) M antibodies, particularly when they are autoantibodies, are not deleterious to the renal allograft. We used the reducing agent dithiotreitol (DTT) to inactivate IgM but not IgG in the crossmatch assay to help sensitized patients have the chance for successful transplantation. In this descriptive study, 57 candidates for kidney transplantation with final positive crossmatches who had a history of panel-reactive antibody (PRA) greater than 30% were selected. Two of 57 patients had systemic lupus erythematous (SLE). The sera of patients were treated by DTT and then measured for cytotoxicity against donor lymphocytes and a panel of 12 cells using the complement-dependent cytotoxicity (CDC) method. Autocrossmatch was also performed to differentiate autoantibodies and alloantibodies by the CDC method. Of the 57 patients, six subjects (10.53%) had IgM and 51 patients (89.47%) IgG in their serum against donor lymphocytes. Also against panel cells, 39 of 57 patients (68.43%) had IgG, three patients (5.26%) had IgM, and 15 patients (26.31%) had both IgG and IgM antibodies. Autolymphocytotoxic antibodies were detected in 1.75% patients (1 of 57) who had SLE. According to our results, 5.26% of the patients who were IgM-positive and IgG-negative for both crossmatch and PRA assays may experience successful kidney transplantation.
Assuntos
Imunoglobulina G/sangue , Imunoglobulina M/sangue , Transplante de Rim/imunologia , Listas de Espera , Citotoxicidade Imunológica , Ditiotreitol , Teste de Histocompatibilidade , Humanos , Isotipos de Imunoglobulinas/sangue , Indicadores e Reagentes , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/imunologiaRESUMO
Previously, we reported that the kaempferol and kaempferol-7-O-glucoside isolated from Securigera securidaca showed potent anti-HSV activity. In the present study the anti-HIV-1 activities of kaempferol and kaempferol-7-O-glucoside are investigated at different concentrations (100, 50, 25 and 10 µg/ml) using HIV-1 p24 Antigen kit. Real-time Polymerase chain reaction (RT-PCR) assay was also used for quantification of full range of virus load observed in treated and untreated cells. According to the results of RT- PCR, tested compounds at a concentration of 100 µg/ml exerted potent inhibitory effect. Time of drug addition experiments demonstrated that these compounds exerted their inhibitory effects on the early stage of HIV infection. The results also showed potent anti-HIV-1 reverse transcriptase activity. Antiviral activity of kaempferol-7-O-glucoside was more pronounced than that of kaempferol. These findings demonstrate that kaempferol-7-O-glucoside could be considered as a new potential drug candidate for the treatment of HIV infection which requires further assessments.